We're excited to announce that we recently completed a COVID-19 treatment trial that leveraged virtual clinical trial solutions and remote patient engagement solutions. Our ePRO/eCOA services brought the trial experience directly to patients & investigators to overcome challenges posed by the pandemic.
IVR Clinical Concepts is included in "the more than 5,000 companies [who] have made public and legally enforceable pledges to protect data transferred from the EU in accordance with the Privacy Shield principles."
Join IVR Clinical Concepts (IVRCC) at the Boston Westin Waterfront for the 11th Outsourcing in Clinical Trials New England conference on October 2-3, 2019. Visit us at Booth #40 to speak with our team about your study needs and the latest technology solutions in clinical trials.
We are very excited with the success of our new technologies and application models, enabling IVRCC to work in a wide range of therapeutic areas to assist you in your clinical trials. Learn about our highlights and new technologies deployed in 2018.
IVRCC has been awarded the role to deliver IRT/RTSM (Interactive Response Technology / Randomization Trial Supply Management) services to support important nicotine dependence research.
IVRCC builds and deploys configurable applications to facilitate the compilation and analysis of retrospective EMR data. Find out how we do it and how our technology supports this important medical work and the FDA's Real-World Evidence Program.
Real-Time Results = Real-Time Success: Drive Better Decisions Faster in Clinical Trials with IVRCC’s Real-Time Reporting Solutions.
Learn how you can drive better decisions faster in clinical trials with IVRCC's real-time reporting solutions.
GDPR, or General Data Protection Regulation, is a set of regulations adopted by the European Union to govern the collection, processing, use and storage of personal data.
IVRCC's new interactive platform features complete modernization, geographic redundancy with real-time mirroring of data and applications across multiple physical sites, a new disaster recovery model with near-real-time mirroring of data and applications for fast response to widespread Internet outages, and a new approach to validation documentation.
The New York Times reported that the FDA recently announced its approval of the first drug designed to prevent migraines. IVRCC has been involved in numerous migraine studies and clinical trials where we've collected daily PRN Pain diaries.